Effect of prostaglandin E.sub.2 injection on the structural properties of the rat patellar tendon

• Published in: Sports medicine, arthroscopy, rehabilitation, therapy, and technology arthroscopy, rehabilitation, therapy, and technology, 2012-01, Vol.4, p.2
• Main Authors: Ferry, Scott T, Afshari, Hessam M, Lee, Justin A, Dahners, Laurence E, Weinhold, Paul S
• Format: Article
• Language: English
• Subjects: Animal experimentation; Anti-inflammatory drugs; Care and treatment; Health aspects; Physiological aspects; Prostaglandins E; Tendinitis
• ISSN: 1758-2555; 1758-2555
• DOI: 10.1186/1758-2555-4-2

Background Increased tendon production of the inflammatory mediator prostaglandin E.sub.2 (PGE.sub.2 ) has been suggested to be a potential etiologic agent in the development of tendinopathy. Repeated injection of PGE.sub.2 into tendon has been proposed as a potential animal model for studying treatments for tendinopathy. In contrast, nonsteroidal anti-inflammatory drugs (NSAIDs) which inhibit PGE.sub.2 production and are commonly prescribed in treating tendinopathy have been shown to impair the healing of tendon after acute injury in animal models. The contradictory literature suggests the need to better define the functional effects of PGE.sub.2 on tendon. Our objective was to characterize the effects of PGE.sub.2 injection on the biomechanical and biochemical properties of tendon and the activity of the animals. Our hypothesis was that weekly PGE.sub.2 injection to the rat patellar tendon would lead to inferior biomechanical properties. Methods Forty rats were divided equally into four groups. Three groups were followed for 4 weeks with the following peritendinous injection procedures: No injection (control), 4 weekly injections of saline (saline), 4 weekly injections of 800 ng PGE.sub.2 (PGE.sub.2 -4 wks). The fourth group received 4 weekly injections of 800 ng PGE.sub.2 initially and was followed for a total of 8 weeks. All animals were injected bilaterally. The main outcome measurements included: the structural and material properties of the patellar tendon under tensile loading to failure, tendon collagen content, and weekly animal activity scores. Results The ultimate load of PGE.sub.2 -4 wks tendons at 4 weeks was significantly greater than control or saline group tendons. The stiffness and elastic modulus of the PGE.sub.2 injected tendons at 8 weeks was significantly greater than the control or saline tendons. No differences in animal activity, collagen content, or mean fibril diameter were observed between groups. Conclusions Four weekly peritendinous injections of PGE.sub.2 to the rat patellar tendon were not found to be an effective model of clinical tendinopathy. In contrast, improved structural and material properties of the patellar tendon were found after PGE.sub.2 injection. While PGE.sub.2 has been thought to have a contributory role in the development of tendinopathy and anti-inflammatory medications remain a common treatment, our results suggest a positive role of PGE.sub.2 in tendon remodeling in some circumstances.